

Angelica LindÃ©n Hirschberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/708877/publications.pdf>

Version: 2024-02-01

147
papers

8,059
citations

50244

46
h-index

56687

83
g-index

149
all docs

149
docs citations

149
times ranked

7452
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Prevalence of Fractures in Congenital Adrenal Hyperplasia: A Swedish Population-based National Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e475-e486.	1.8	17
2	Analysis of Neurodevelopmental Disorders in Offspring of Mothers With Eating Disorders in Sweden. <i>JAMA Network Open</i> , 2022, 5, e2143947.	2.8	15
3	Challenging Aspects of Research on the Influence of the Menstrual Cycle and Oral Contraceptives on Physical Performance. <i>Sports Medicine</i> , 2022, 52, 1453-1456.	3.1	12
4	The impact of adherence and therapy regimens on quality of life in patients with congenital adrenal hyperplasia. <i>Clinical Endocrinology</i> , 2022, 96, 666-679.	1.2	5
5	Sexual Function in Women with Differences of Sex Development or Premature Loss of Gonadal Function. <i>Journal of Sexual Medicine</i> , 2022, 19, 249-256.	0.3	1
6	The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement. <i>Maturitas</i> , 2022, 158, 70-77.	1.0	24
7	Molecular Regulators of Muscle Mass and Mitochondrial Remodeling Are Not Influenced by Testosterone Administration in Young Women. <i>Frontiers in Endocrinology</i> , 2022, 13, 874748.	1.5	3
8	Klotho Polymorphism in Association With Serum Testosterone and Knee Strength in Women After Testosterone Administration. <i>Frontiers in Physiology</i> , 2022, 13, .	1.3	4
9	Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. <i>Maturitas</i> , 2022, 163, 1-14.	1.0	33
10	Reproductive and Perinatal Outcomes in Women with Congenital Adrenal Hyperplasia: A Population-based Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e957-e965.	1.8	27
11	Management of urinary incontinence in postmenopausal women: An EMAS clinical guide. <i>Maturitas</i> , 2021, 143, 223-230.	1.0	27
12	Disposition of Urinary and Serum Steroid Metabolites in Response to Testosterone Administration in Healthy Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 697-707.	1.8	23
13	Higher blood pressure in normal weight women with PCOS compared to controls. <i>Endocrine Connections</i> , 2021, 10, 154-163.	0.8	13
14	Posterior compartment symptoms in primiparous women 1 year after non-assisted vaginal deliveries: a Swedish cohort study. <i>International Urogynecology Journal</i> , 2021, 32, 1825-1832.	0.7	5
15	Treatment with assisted reproduction technologies in women with acute hepatic porphyria. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1712-1721.	1.3	3
16	Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. <i>Maturitas</i> , 2021, 148, 55-61.	1.0	35
17	Urinary Steroid Profile in Elite Female Athletes in Relation to Serum Androgens and in Comparison With Untrained Controls. <i>Frontiers in Physiology</i> , 2021, 12, 702305.	1.3	9
18	Interaction between insulin and androgen signalling in decidualization, cell migration and trophoblast invasion <i>in vitro</i> . <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9523-9532.	1.6	8

#	ARTICLE	IF	CITATIONS
19	IGF-I and IGFBP-1 in Relation to Body Composition and Physical Performance in Female Olympic Athletes. <i>Frontiers in Endocrinology</i> , 2021, 12, 708421.	1.5	3
20	Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement. <i>Maturitas</i> , 2021, 151, 55-62.	1.0	28
21	A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. <i>Psychoneuroendocrinology</i> , 2021, 133, 105426.	1.3	26
22	Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2063-e2077.	1.8	38
23	Female Hyperandrogenism in Elite Sports and the Athletic Triad. <i>Seminars in Reproductive Medicine</i> , 2021, , .	0.5	1
24	Association between prolactin receptor expression and proliferation in the endometrium of obese women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2020, 36, 226-232.	0.7	13
25	Women with polycystic ovary syndrome present with altered endometrial expression of stanniocalcin-1. <i>Biology of Reproduction</i> , 2020, 102, 306-315.	1.2	15
26	Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. <i>Maturitas</i> , 2020, 131, 91-101.	1.0	37
27	Association of Maternal Eating Disorders With Pregnancy and Neonatal Outcomes. <i>JAMA Psychiatry</i> , 2020, 77, 285.	6.0	41
28	The Mediterranean diet and menopausal health: An EMAS position statement. <i>Maturitas</i> , 2020, 139, 90-97.	1.0	39
29	Insulin regulation of solute carrier family 2 member 1 (glucose transporter 1) expression and glucose uptake in decidualizing human endometrial stromal cells: an in vitro study. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, 117.	1.4	4
30	OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	1
31	Enhanced Skeletal Muscle Oxidative Capacity and Capillary-to-Fiber Ratio Following Moderately Increased Testosterone Exposure in Young Healthy Women. <i>Frontiers in Physiology</i> , 2020, 11, 585490.	1.3	10
32	Digit Ratio (2D:4D) and Physical Performance in Female Olympic Athletes. <i>Frontiers in Endocrinology</i> , 2020, 11, 292.	1.5	18
33	Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: Lifestyle management. <i>Obesity Reviews</i> , 2020, 21, e13046.	3.1	41
34	A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting. <i>Oncologist</i> , 2020, 25, e1846-e1854.	1.9	13
35	Endometrial expression of anti-Müllerian hormone and its type II receptor in women with polycystic ovary syndrome. <i>Reproductive BioMedicine Online</i> , 2020, 41, 128-137.	1.1	5
36	Fiber type-specific hypertrophy and increased capillarization in skeletal muscle following testosterone administration in young women. <i>Journal of Applied Physiology</i> , 2020, 128, 1240-1250.	1.2	23

#	ARTICLE	IF	CITATIONS
37	Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. <i>Maturitas</i> , 2020, 135, 82-88.	1.0	51
38	Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. <i>Menopause</i> , 2020, 27, 526-534.	0.8	25
39	The role of testosterone in menopausal hormone treatment. What is the evidence?. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2020, 99, 966-969.	1.3	7
40	Dihydrotestosterone potentiates insulin to upregulate prokineticin-1 in decidualizing human endometrial stromal cells. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 3242-3245.	1.6	11
41	Effects of moderately increased testosterone concentration on physical performance in young women: a double blind, randomised, placebo controlled study. <i>British Journal of Sports Medicine</i> , 2020, 54, 599-604.	3.1	60
42	Editorial: Exercise and Sport: Their Influences on Women's Health Across the Lifespan. <i>Frontiers in Physiology</i> , 2020, 11, 615468.	1.3	0
43	Female hyperandrogenism and elite sport. <i>Endocrine Connections</i> , 2020, 9, R81-R92.	0.8	30
44	Psychological well-being and personality in relation to weight loss following behavioral modification intervention in obese women with polycystic ovary syndrome: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2020, 183, 1-11.	1.9	30
45	The digit ratio (2D:4D) and economic preferences: no robust associations in a sample of 330 women. <i>Journal of the Economic Science Association</i> , 2019, 5, 149-169.	1.8	15
46	Changes in premenstrual symptoms in women starting or discontinuing use of oral contraceptives. <i>Gynecological Endocrinology</i> , 2019, 35, 422-426.	0.7	5
47	Mice exposed to maternal androgen excess and diet-induced obesity have altered phosphorylation of catechol-O-methyltransferase in the placenta and fetal liver. <i>International Journal of Obesity</i> , 2019, 43, 2176-2188.	1.6	16
48	Increased Risk of Autoimmune Disorders in 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. <i>Journal of the Endocrine Society</i> , 2019, 3, 1039-1052.	0.1	8
49	Impact of hormonal contraceptives on urinary steroid profile in relation to serum hormone changes and CYP17A1 polymorphism. <i>Drug Testing and Analysis</i> , 2019, 11, 1284-1289.	1.6	13
50	Exercise Recommendations for Women with Polycystic Ovary Syndrome: Is the Evidence Enough?. <i>Sports Medicine</i> , 2019, 49, 1143-1157.	3.1	36
51	Effects of drospirenone and norethisterone acetate combined with estradiol on mammographic density and proliferation of breast epithelial cells—A prospective randomized trial. <i>Maturitas</i> , 2019, 126, 18-24.	1.0	9
52	Sexuality in Adults with Differences/Disorders of Sex Development (DSD): Findings from the dsd-LIFE Study. <i>Journal of Sex and Marital Therapy</i> , 2019, 45, 688-705.	1.0	23
53	Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 256-266.	5.5	106
54	Improved menstrual function in obese women with polycystic ovary syndrome after behavioural modification intervention—A randomized controlled trial. <i>Clinical Endocrinology</i> , 2019, 90, 468-478.	1.2	23

#	ARTICLE	IF	CITATIONS
55	Hyperandrogenism in Female Athletes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 503-505.	1.8	11
56	Sport and Menses. , 2019, , 461-470.		2
57	Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 141-145.	1.4	5
58	MON-217 Maternal Androgen Excess and Obesity Induce Cardiac Hypertrophy and Left Ventricular Dysfunction in Female Offspring. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
59	Pregnancy greatly affects the steroidal module of the Athlete Biological Passport. <i>Drug Testing and Analysis</i> , 2018, 10, 1070-1075.	1.6	12
60	Hormonal Contraceptives Do Not Impact Economic Preferences: Evidence from a Randomized Trial. <i>Management Science</i> , 2018, 64, 4515-4532.	2.4	19
61	Prokineticin 1 is upregulated by insulin in decidualizing human endometrial stromal cells. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 163-172.	1.6	19
62	Letter to the editor: Sex and the eye test. <i>Psychoneuroendocrinology</i> , 2018, 98, 242-243.	1.3	0
63	Impact of Human Cytomegalovirus Infection and its Immune Response on Survival of Patients with Ovarian Cancer. <i>Translational Oncology</i> , 2018, 11, 1292-1300.	1.7	28
64	Maternal androgen excess and obesity induce sexually dimorphic anxiety-like behavior in the offspring. <i>FASEB Journal</i> , 2018, 32, 4158-4171.	0.2	37
65	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2018, 110, 364-379.	0.5	759
66	Serum androgen levels are positively correlated with athletic performance and competition results in elite female athletes. <i>British Journal of Sports Medicine</i> , 2018, 52, 1531-1532.	3.1	38
67	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. <i>Human Reproduction</i> , 2018, 33, 1602-1618.	0.4	1,015
68	Cognitive abilities in women with complete androgen insensitivity syndrome and women with gonadal dysgenesis. <i>Psychoneuroendocrinology</i> , 2018, 98, 233-241.	1.3	3
69	Role of testosterone and Y chromosome genes for the masculinization of the human brain. <i>Human Brain Mapping</i> , 2017, 38, 1801-1814.	1.9	47
70	Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. <i>Fertility and Sterility</i> , 2017, 107, 788-795.e2.	0.5	81
71	Treatment of premenstrual dysphoric disorder with the GABA A receptor modulating steroid antagonist Sepranolone (UC1010)â€”A randomized controlled trial. <i>Psychoneuroendocrinology</i> , 2017, 80, 46-55.	1.3	93
72	Effect of age on serum prostate-specific antigen in women. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, e271-e272.	1.4	3

#	ARTICLE	IF	CITATIONS
73	A first-choice combined oral contraceptive influences general well-being in healthy women: a double-blind, randomized, placebo-controlled trial. <i>Fertility and Sterility</i> , 2017, 107, 1238-1245.	0.5	57
74	Progesterone Receptors and Proliferation of the Endometrium in Obese Women With Polycystic Ovary Syndromeâ€”A Lifestyle Intervention Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1244-1253.	1.8	15
75	The prevalence of Type 2 diabetes is not increased in normal-weight women with PCOS. <i>Human Reproduction</i> , 2017, 32, 2279-2286.	0.4	40
76	Fertility outcome and information on fertility issues in individuals with different forms of disorders of sex development: findings from the dsd-LIFE study. <i>Fertility and Sterility</i> , 2017, 108, 822-831.	0.5	55
77	Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16â€”26 years: a randomised, double-blind trial. <i>Lancet, The</i> , 2017, 390, 2143-2159.	6.3	314
78	In Reply:. <i>Menopause</i> , 2017, 24, 232-233.	0.8	0
79	Increased psychiatric morbidity in women with complete androgen insensitivity syndrome or complete gonadal dysgenesis. <i>Journal of Psychosomatic Research</i> , 2017, 101, 122-127.	1.2	22
80	Serum androgen profile and physical performance in women Olympic athletes. <i>British Journal of Sports Medicine</i> , 2017, 51, 1301-1308.	3.1	57
81	Are carriers of <i>CYP21A2</i> mutations less vulnerable to psychological stress? A population-based national cohort study. <i>Clinical Endocrinology</i> , 2017, 86, 317-324.	1.2	8
82	Reduced Frequency of Biological and Increased Frequency of Adopted Children in Males With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4191-4199.	1.8	50
83	SERUM ANDROGEN PROFILE, BODY COMPOSITION AND PHYSICAL PERFORMANCE IN FEMALE OLYMPIC ATHLETES. <i>British Journal of Sports Medicine</i> , 2017, 51, 296.1-296.	3.1	0
84	Serum complexed and free prostate specific antigen levels are lower in female elite athletes in comparison to control women. <i>F1000Research</i> , 2017, 6, 1131.	0.8	7
85	Dysregulation of In Vitro Decidualization of Human Endometrial Stromal Cells by Insulin via Transcriptional Inhibition of Forkhead Box Protein O1. <i>PLoS ONE</i> , 2017, 12, e0171004.	1.1	38
86	Should we individualize lipid profiling in women with polycystic ovary syndrome?. <i>Human Reproduction</i> , 2016, 31, 2791-2795.	0.4	9
87	Combined Oral Contraceptives and Sexual Function in Womenâ€”a Double-Blind, Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4046-4053.	1.8	45
88	Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. <i>Menopause</i> , 2016, 23, 593-599.	0.8	64
89	Endometrial Expression of Estrogen Receptors and the Androgen Receptor in Women With Polycystic Ovary Syndrome: A Lifestyle Intervention Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 561-571.	1.8	33
90	Serum Androgen Levels and Sexual Function Before and One Year After Treatment of Uterine Cervical Cancer: A Pilot Study. <i>Journal of Sexual Medicine</i> , 2016, 13, 413-424.	0.3	14

#	ARTICLE	IF	CITATIONS
91	Lost workdays in uterine cervical cancer survivors compared to the general population: impact of treatment and relapse. <i>Journal of Cancer Survivorship</i> , 2016, 10, 514-523.	1.5	8
92	“It’s Part of Me, Not All of Me”: Young Women’s Experiences of Receiving a Diagnosis Related to Diverse Sex Development. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2016, 29, 338-343.	0.3	25
93	Biomarkers of nutrition and stress in pregnant women with a history of eating disorders in relation to head circumference and neurocognitive function of the offspring. <i>BMC Pregnancy and Childbirth</i> , 2015, 15, 318.	0.9	16
94	Hormone therapy after uterine cervical cancer treatment. <i>Menopause</i> , 2015, 22, 633-639.	0.8	19
95	Congenital Adrenal Hyperplasia, Polycystic Ovary Syndrome and criminal behavior: A Swedish population based study. <i>Psychiatry Research</i> , 2015, 229, 953-959.	1.7	12
96	Identification and prediction of the fertile window using NaturalCycles. <i>European Journal of Contraception and Reproductive Health Care</i> , 2015, 20, 403-408.	0.6	62
97	Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: A total population study. <i>Psychoneuroendocrinology</i> , 2015, 60, 195-205.	1.3	96
98	Increased Cardiovascular and Metabolic Morbidity in Patients With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3520-3528.	1.8	153
99	Sex hormone levels as determinants of bone mineral density and osteoporosis in Vietnamese women and men. <i>Journal of Bone and Mineral Metabolism</i> , 2015, 33, 658-665.	1.3	21
100	Effects of estrogen and testosterone treatment on serotonin transporter binding in the brain of surgically postmenopausal women – a PET study. <i>NeuroImage</i> , 2015, 106, 47-54.	2.1	33
101	The Impact of Genetics and Hormonal Contraceptives on the Steroid Profile in Female Athletes. <i>Frontiers in Endocrinology</i> , 2014, 5, 50.	1.5	24
102	Increased Mortality in Patients With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2715-E2721.	1.8	138
103	Estrogenic action on innate defense mechanisms in the urinary tract. <i>Maturitas</i> , 2014, 77, 32-36.	1.0	75
104	Serum Androgen Levels in Elite Female Athletes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4328-4335.	1.8	84
105	Serum anti-Müllerian hormone in response to dietary management and/or physical exercise in overweight/obese women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial. <i>Fertility and Sterility</i> , 2013, 100, 1096-1102.	0.5	60
106	Cognitive function in association with sex hormones in postmenopausal women. <i>Gynecological Endocrinology</i> , 2013, 29, 59-62.	0.7	60
107	Are the New Policies on Hyperandrogenism in Elite Female Athletes Really Out of Bounds? Response to “Out of Bounds? A Critique of the New Policies on Hyperandrogenism in Elite Female Athletes” <i>American Journal of Bioethics</i> , 2013, 13, 63-65.	0.5	27
108	Oral Contraceptives Do Not Affect Muscle Strength and Hop Performance in Active Women. <i>Clinical Journal of Sport Medicine</i> , 2013, 23, 202-207.	0.9	27

#	ARTICLE	IF	CITATIONS
109	Body Composition and Endocrine Profile of Male Olympic Athletes Striving for Leanness. <i>Clinical Journal of Sport Medicine</i> , 2013, 23, 197-201.	0.9	41
110	Estrogen Supports Urothelial Defense Mechanisms. <i>Science Translational Medicine</i> , 2013, 5, 190ra80.	5.8	109
111	Sex hormones, appetite and eating behaviour in women. <i>Maturitas</i> , 2012, 71, 248-256.	1.0	200
112	The Influence of Menstrual Phases on Pain Modulation in Healthy Women. <i>Journal of Pain</i> , 2012, 13, 646-655.	0.7	80
113	A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women. <i>Fertility and Sterility</i> , 2011, 95, 152-157.	0.5	41
114	Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2011, 96, 1508-1513.	0.5	110
115	A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. <i>Menopause</i> , 2010, 17, 72-79.	0.8	27
116	Polycystic Ovary Syndrome, Obesity and Reproductive Implications. <i>Women's Health</i> , 2009, 5, 529-542.	0.7	54
117	The Effect of Transdermal Testosterone on Mammographic Density in Postmenopausal Women Not Receiving Systemic Estrogen Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4907-4913.	1.8	36
118	A randomized trial of the effect of estrogen and testosterone on economic behavior. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6535-6538.	3.3	164
119	Hyperandrogenism May Explain Reproductive Dysfunction in Olympic Athletes. <i>Medicine and Science in Sports and Exercise</i> , 2009, 41, 1241-1248.	0.2	95
120	Early maternal adjustment in women with eating disorders. <i>International Journal of Eating Disorders</i> , 2008, 41, 405-410.	2.1	55
121	Prospective follow-up of menstrual disorders in adolescence and prognostic factors. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2008, 87, 1162-1168.	1.3	69
122	Key lipogenic gene expression can be decreased by estrogen in human adipose tissue. <i>Fertility and Sterility</i> , 2008, 90, 44-48.	0.5	82
123	Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen. <i>New England Journal of Medicine</i> , 2008, 359, 2005-2017.	13.9	427
124	Special Attention to the Weight-Control Strategies Employed by Olympic Athletes Striving for Leanness Is Required. <i>Clinical Journal of Sport Medicine</i> , 2008, 18, 5-9.	0.9	40
125	Effects of Testosterone Treatment on Endometrial Proliferation in Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2169-2175.	1.8	51
126	An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. <i>Menopause</i> , 2007, 14, 89-96.	0.8	46

#	ARTICLE	IF	CITATIONS
127	Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. <i>Menopause</i> , 2007, 14, 183-190.	0.8	99
128	Effects of testosterone and estrogen treatment on lipolysis signaling pathways in subcutaneous adipose tissue of postmenopausal women. <i>Fertility and Sterility</i> , 2007, 88, 100-106.	0.5	38
129	Plasma ghrelin and gastric pacing in morbidly obese patients. <i>Metabolism: Clinical and Experimental</i> , 2007, 56, 1017-1021.	1.5	14
130	Menstrual disorders and associated factors among adolescent girls visiting a youth clinic. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2007, 86, 65-72.	1.3	47
131	Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. <i>Fertility and Sterility</i> , 2006, 86, 136-144.	0.5	62
132	Knee joint kinaesthesia and neuromuscular coordination during three phases of the menstrual cycle in moderately active women. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2006, 14, 383-389.	2.3	29
133	Bone mineral density in bulimic women – influence of endocrine factors and previous anorexia. <i>European Journal of Endocrinology</i> , 2006, 155, 245-251.	1.9	55
134	Polycystic ovary syndrome in bulimic women – an evaluation based on the new diagnostic criteria. <i>Gynecological Endocrinology</i> , 2006, 22, 388-394.	0.7	49
135	Pregnancy and Neonatal Outcomes in Women With Eating Disorders. <i>Obstetrics and Gynecology</i> , 2005, 105, 255-260.	1.2	184
136	Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 352-360.	0.7	58
137	Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. <i>Clinical Endocrinology</i> , 2005, 63, 450-455.	1.2	49
138	Altered Postural Control during the Luteal Phase in Women with Premenstrual Symptoms. <i>Neuroendocrinology</i> , 2005, 81, 150-157.	1.2	32
139	Oral Contraceptives Improve Endothelial Function in Amenorrheic Athletes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3162-3167.	1.8	64
140	Amenorrhea in Female Athletes Is Associated with Endothelial Dysfunction and Unfavorable Lipid Profile. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1354-1359.	1.8	151
141	Diurnal Profiles of Testosterone and Pituitary Hormones Suggest Different Mechanisms for Menstrual Disturbances in Endurance Athletes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 702-707.	1.8	75
142	Effects of Oral Contraceptives on Body Composition and Physical Performance in Female Athletes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4364-4370.	1.8	103
143	Hyperandrogenicity is an alternative mechanism underlying oligomenorrhea or amenorrhea in female athletes and may improve physical performance. <i>Fertility and Sterility</i> , 2003, 79, 947-955.	0.5	98
144	Muscle Strength and Endurance Do Not Significantly Vary Across 3 Phases of the Menstrual Cycle in Moderately Active Premenopausal Women. <i>Clinical Journal of Sport Medicine</i> , 2003, 13, 238-241.	0.9	69

#	ARTICLE	IF	CITATIONS
145	Altered adrenal steroid metabolism underlying hypercortisolism in female endurance athletes. <i>Fertility and Sterility</i> , 1995, 63, 1190-1194.	0.5	24
146	The Digit Ratio (2D:4D) and Economic Preferences: No Robust Associations in a Sample of 330 Women. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
147	Female hyperandrogenism and elite sport. <i>Endocrine Abstracts</i> , 0, , .	0.0	0